Titre :

Absence of impact of direct acting antivirals for hepatitis c virus on recurrent hepatocellular carcinoma tumor growth in the afef/anrs co22 hepather cohort

Auteur(s) :

Vallet-Pichard, Anais [Auteur]
Correas, Jean-Michel [Auteur]
Dorival, Celine [Auteur]
Zoulim, Fabien [Auteur]
Tran, Albert [Auteur]
Bourliere, Marc [Auteur]
Cales, Paul [Auteur]
Guyader, Dominique [Auteur]
Bronowicki, Jean-Pierre [Auteur]
Larrey, Dominique [Auteur]
Hezode, Christophe [Auteur]
Loustaud-Ratti, Veronique [Auteur]
Gournay, Jerome [Auteur]
De Ledinghen, Victor [Auteur]
Asselah, Tarik [Auteur]
Ganne-Carrie, Nathalie [Auteur]
Metivier, Sophie [Auteur]
Chazouilleres, Olivier [Auteur]
Leroy, Vincent [Auteur]
Rosa, Isabelle [Auteur]
Samuel, Didier [Auteur]
Mathurin, Philippe [Auteur]
Cagnot, Carole [Auteur]
Fontaine, Helene [Auteur]
Carrat, Fabrice [Auteur]
Pol, Stanislas [Auteur]

Titre de la revue :

Clinics and research in hepatology and gastroenterology

Nom court de la revue :

Clin Res Hepatol Gastroenterol

Date de publication :

2020-06-25

ISSN :

2210-741X

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

BACKGROUND: Although it has now been excluded that direct-acting antivirals (DAA) are associated with a significant risk of hepatocellular carcinoma (HCC) in HCV-infected patients, a possible effect of DAA on tumor growth ...
Lire la suite >BACKGROUND: Although it has now been excluded that direct-acting antivirals (DAA) are associated with a significant risk of hepatocellular carcinoma (HCC) in HCV-infected patients, a possible effect of DAA on tumor growth is still a subject of debate. We performed a blind comparison of the kinetics of HCC recurrence in patients after HCV treatment with or without DAA to evaluate the potential aggressiveness of HCC after DAA treatment. METHODS: Thirty-nine HCV-infected patients from the AFEF/ANRS CO22 Hepather cohort who experienced HCC recurrence after so-called curative treatment were evaluated. Contrast-enhanced CT and/or MR images were read blindly 6 months before HCC recurrence and during the follow-up period. Seventeen patients who received DAA (DAA+) before HCC recurrence were compared to the 22 who did not receive (DAA-), according to the LiRads and mRECIST criteria. RESULTS: There were 28 men and 11 women, median age 62 years old, 37 (95%) with cirrhosis. DAA+ patients had a lower median MELD score (8±2 vs. 10±4, P=0.0286) than DAA- patients. The median time to HCC recurrence (time from the date of curative treatment to the diagnosis of recurrence) was not different (20 vs. 18 months) (P=0.73) between the two groups. There was no difference between the 2 groups in the overall survival and/or transplantation-free survival (P=0.71) and for the mRECIST time to progression (P=0.25). CONCLUSIONS: This blinded analysis of HCC recurrence after HCC treatment does not support any negative impact of DAA therapy on the severity or progression of recurrent HCC.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2021-07-06T12:45:05Z